BioSpace News Archive

ScriptSender, a leader in enabling secure, one-click communication between healthcare providers, announced a partnership with openDoctor, a leader in scheduling technology for the radiology industry.

After a thorough and comprehensive review, the Canadian Food Inspection Agency cancelled three Safe Food for Canadian licences.

Health Canada has been working to address the issue of N-nitrosodimethylamine and similar nitrosamine impurities found in certain “sartan” angiotensin receptor blocker blood pressure medications since 2018 and, certain ranitidine drugs more recently.

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Court of Common Pleas for Franklin County, Ohio (the “Ohio Court”) issued a ruling in favor of Navidea in its case against Capital Royalty Partners II, L.P., et al (“CRG”).

For the first time, scientists have linked memory impairment in mammals with the expression of endogenous retroviruses (ERVs) within an organism’s genome.

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted non-statutory stock options to purchase an aggregate of 18,000 ordinary shares of Nabriva Therapeutics as inducements to 4 newly-hired employees.

Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company pioneering advancements of cell therapies in select cardiovascular and autoimmune diseases, announced today that the Company will present at the following conferences in December:

ViewRay, Inc. (Nasdaq: VRAY) announced today that it has signed a non-binding memorandum of understanding for collaboration with Elekta AB (Nasdaq: EKTA-B.ST) (“Elekta”) to advance the knowledge and use of MR-guided radiation therapy. In connection with the collaboration, Elekta has committed to invest capital for up to a 9.9% minority interest in ViewRay

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Tuesday, December 3, 2019, to provide top-line results from Part 1 of the adaptive Phase 3 RENEW Trial of topical ocular reproxalap in patients with dry eye disease.

Cerner Corporation, a global health care technology company, has achieved its 500th patent, a new innovative voice-assisted technology designed to make it easier for clinicians to document the details of a patient visit on a mobile device.